ACHL实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (18 May 2024 @ 04:00):

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors...

Stats
今日成交量	115 040
平均成交量	582 007
市值	38.94M
EPS	$0 ( 2024-05-08 )
下一个收益日期	( $-0.410 ) 2024-08-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.590
ATR14	$0.0200 (2.11%)

Achilles Therapeutics plc 相关性

10 最正相关
CRSP	0.844
SGMO	0.843
GRPN	0.833
NUVL	0.821
ANGI	0.818
FONR	0.806

10 最负相关
RGLD	-0.876

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Achilles Therapeutics plc 相关性 - 货币/商品

0.10
( neutral )

0.01
( neutral )

0.00
( neutral )

-0.38
( neutral )

Achilles Therapeutics plc 财务报表

Annual	2023
营收:	$0
毛利润:	$-4.73M (0.00 %)
EPS:	$-1.750

FY	2023
营收:	$0
毛利润:	$-4.73M (0.00 %)
EPS:	$-1.750

FY	2022
营收:	$0
毛利润:	$-3.69M (0.00 %)
EPS:	$-1.820

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.36

Financial Reports:

No articles found.

Achilles Therapeutics plc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Achilles Therapeutics plc

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.